Aberrant induction of p19Arf-mediated cellular senescence contributes to neurodevelopmental defects.
Muriel RhinnIrene Zapata-BodaloAnnabelle KleinJean-Luc PlassatTania Knauer-MeyerWilliam M KeyesPublished in: PLoS biology (2022)
Valproic acid (VPA) is a widely prescribed drug to treat epilepsy, bipolar disorder, and migraine. If taken during pregnancy, however, exposure to the developing embryo can cause birth defects, cognitive impairment, and autism spectrum disorder. How VPA causes these developmental defects remains unknown. We used embryonic mice and human organoids to model key features of VPA drug exposure, including exencephaly, microcephaly, and spinal defects. In the malformed tissues, in which neurogenesis is defective, we find pronounced induction of cellular senescence in the neuroepithelial (NE) cells. Critically, through genetic and functional studies, we identified p19Arf as the instrumental mediator of senescence and microcephaly, but, surprisingly, not exencephaly and spinal defects. Together, these findings demonstrate that misregulated senescence in NE cells can contribute to developmental defects.
Keyphrases
- endothelial cells
- bipolar disorder
- autism spectrum disorder
- induced apoptosis
- dna damage
- zika virus
- cognitive impairment
- intellectual disability
- spinal cord
- cell cycle arrest
- stress induced
- gene expression
- cell death
- adverse drug
- metabolic syndrome
- blood brain barrier
- copy number
- subarachnoid hemorrhage
- neural stem cells